Geovax Labs Inc Stock OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
03-28 | GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.92M 5.34M |
---|---|---|---|---|---|
Net income 2024 * | -31M -42.16M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.41% |
Latest transcript on Geovax Labs Inc
Managers | Title | Age | Since |
---|---|---|---|
David Dodd
CEO | Chief Executive Officer | 74 | 10-03-16 |
Mark Reynolds
DFI | Director of Finance/CFO | 62 | 06-09-30 |
Erica Raiden
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert McNally
BRD | Director/Board Member | 76 | 06-11-30 |
Randal Chase
BRD | Director/Board Member | 74 | 15-03-18 |
John Spencer
BRD | Director/Board Member | 83 | 06-09-27 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |